Evidence map›Paper›PMID 35492945›Full record

ArticleRSC advances2020

A novel strategy for the characterization of glaucocalyxin A metabolites

Wenjing Sun, Yiran Jin, Shuai Guan, Mengxin Yang, Miaoting Zhang, Jiali Hou, Yingfeng Du

Abstract read
In one paragraph

Article in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wenjing SunDepartment of Pharmaceutical Analysis, School of Pharmacy, Hebei Medical University 361 East Zhongshan Road Shijiazhuang Hebei 050017 P. R. China yingfengdu@126.com +86-311-86266419 +86-311-86265625.
Yiran JinThe Second Hospital of Hebei Medical University Shijiazhuang Hebei 050000 P. R. China.
Shuai GuanThe Second Hospital of Hebei Medical University Shijiazhuang Hebei 050000 P. R. China.
Mengxin YangDepartment of Pharmaceutical Analysis, School of Pharmacy, Hebei Medical University 361 East Zhongshan Road Shijiazhuang Hebei 050017 P. R. China yingfengdu@126.com +86-311-86266419 +86-311-86265625.
Miaoting ZhangDepartment of Pharmaceutical Analysis, School of Pharmacy, Hebei Medical University 361 East Zhongshan Road Shijiazhuang Hebei 050017 P. R. China yingfengdu@126.com +86-311-86266419 +86-311-86265625.
Jiali HouDepartment of Pharmaceutical Analysis, School of Pharmacy, Hebei Medical University 361 East Zhongshan Road Shijiazhuang Hebei 050017 P. R. China yingfengdu@126.com +86-311-86266419 +86-311-86265625.
Yingfeng DuDepartment of Pharmaceutical Analysis, School of Pharmacy, Hebei Medical University 361 East Zhongshan Road Shijiazhuang Hebei 050017 P. R. China yingfengdu@126.com +86-311-86266419 +86-311-86265625.ORCID https://orcid.org/0000-0002-2775-6698

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glaucocalyxin A (GLA) belongs to the natural ent-kauranoid diterpenoids family with antitumor, antifibrotic, anticoagulative, antioxidant, and anti-AD effects. In this study, ultra-high-performance liquid chromatography coupled to quadrupole time-of-flight mass spectrometry (UHPLC-Q-TOF-MS) system was applied to observe probable metabolites of GLA

Identifiers

PMID35492945
PMCPMC9050391

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.